BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9525721)

  • 1. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion.
    Broaddus WC; Prabhu SS; Gillies GT; Neal J; Conrad WS; Chen ZJ; Fillmore H; Young HF
    J Neurosurg; 1998 Apr; 88(4):734-42. PubMed ID: 9525721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion.
    Broaddus WC; Prabhu SS; Gillies GT; Neal J; Conrad WS; Chen ZJ; Fillmore H; Young HF
    Neurosurg Focus; 1997 Nov; 3(5):Article4. PubMed ID: 17206780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative three-dimensional analysis and diffusion modeling of oligonucleotide concentrations after direct intraparenchymal brain infusion.
    Haar PJ; Stewart JE; Gillies GT; Prabhu SS; Broaddus WC
    IEEE Trans Biomed Eng; 2001 May; 48(5):560-9. PubMed ID: 11341530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
    Wu D; Boado RJ; Pardridge WM
    J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of the cellular uptake of phosphorothioate oligodeoxynucleotides in the rat kidney in vivo.
    Carome MA; Kang YH; Bohen EM; Nicholson DE; Carr FE; Kiandoli LC; Brummel SE; Yuan CM
    Nephron; 1997; 75(1):82-7. PubMed ID: 9031275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion.
    Grindel JM; Musick TJ; Jiang Z; Roskey A; Agrawal S
    Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):43-52. PubMed ID: 9512095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide.
    Temsamani J; Roskey A; Chaix C; Agrawal S
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
    Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.
    Zhang R; Lu Z; Zhang X; Zhao H; Diasio RB; Liu T; Jiang Z; Agrawal S
    Clin Chem; 1995 Jun; 41(6 Pt 1):836-43. PubMed ID: 7768001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat.
    Peng B; Andrews J; Nestorov I; Brennan B; Nicklin P; Rowland M
    Antisense Nucleic Acid Drug Dev; 2001 Feb; 11(1):15-27. PubMed ID: 11258618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
    Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
    J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyethylenimine but not cationic lipid improves antisense activity of 3'-capped phosphodiester oligonucleotides.
    Dheur S; Dias N; van Aerschot A; Herdewijn P; Bettinger T; Rémy JS; Hélène C; Saison-Behmoaras ET
    Antisense Nucleic Acid Drug Dev; 1999 Dec; 9(6):515-25. PubMed ID: 10645777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.
    Zhang R; Yan J; Shahinian HK; Amin G; Lu Z; Liu T; Saag MS; Jiang Z; Temsamani J; Martin RR
    Clin Pharmacol Ther; 1995 Jul; 58(1):44-53. PubMed ID: 7628182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection.
    Soni PN; Brown D; Saffie R; Savage K; Moore D; Gregoriadis G; Dusheiko GM
    Hepatology; 1998 Nov; 28(5):1402-10. PubMed ID: 9794928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
    Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery.
    Gomes dos Santos AL; Bochot A; Doyle A; Tsapis N; Siepmann J; Siepmann F; Schmaler J; Besnard M; Behar-Cohen F; Fattal E
    J Control Release; 2006 May; 112(3):369-81. PubMed ID: 16644054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice.
    Rifai A; Brysch W; Fadden K; Clark J; Schlingensiepen KH
    Am J Pathol; 1996 Aug; 149(2):717-25. PubMed ID: 8702009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion.
    Iversen PL; Mata J; Tracewell WG; Zon G
    Antisense Res Dev; 1994; 4(1):43-52. PubMed ID: 8061515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety.
    Schlingensiepen R; Goldbrunner M; Szyrach MN; Stauder G; Jachimczak P; Bogdahn U; Schulmeyer F; Hau P; Schlingensiepen KH
    Oligonucleotides; 2005; 15(2):94-104. PubMed ID: 15989424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats.
    Lendvai G; Velikyan I; Bergström M; Estrada S; Laryea D; Välilä M; Salomäki S; Långström B; Roivainen A
    Eur J Pharm Sci; 2005 Sep; 26(1):26-38. PubMed ID: 15941654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.